How to Participate or Opt-Out of the Pending EpiPen Class-Action Lawsuit


Know your options and take action if necessary

As we’ve covered here on, Mylan and Pfizer (among others) are defendants in two class-action lawsuits that allege the companies raised the price of the device 500% and sought to limit competition with other drugmakers by offering insurance companies incentives not to reimburse other brands.

One suit — predicated on the alleged violation of racketeering laws — is open to all consumers who purchased EpiPens after August 24, 2011.

Click to visit sponsor

The other, involving individual state anti-trust laws, is open to consumers in certain states who purchased their EpiPens after January 28, 2013. These states include Alabama, California, Florida, Hawaii, Illinois, Kansas, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New York, North Carolina, Tennessee, and Utah.

The trial is set to begin April 2021.

If you wish to participate in one or both of these lawsuits you need do nothing; you should receive notification about pending proceedings.

Click to visit sponsor

To learn more or if you do not wish to participate — such as if you wish to pursue litigation on your own — click here.

Note: this class-action pertains only to Mylan’s EpiPen brand epinephrine auto-injectors and Mylan authorized generics. They do not pertain to Kaleo’s Auvi-Q or Teva and Amneal’s devices.

Ruling Allows Millions to Join Lawsuit in EpiPen Racketeering Case
Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.